http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
진행성 비소세포폐암 환자에서 Vinorelbine, Ifosfamide 복합화학요법
조은경(Eun Kyung Cho),홍순홍(Soon Hong Hong),방수미(Soo Mee Bang),이한경(Han Kyung Lee),박정웅(Jeong Woong Park),정성환(Seong Hwan Jeong),남귀현(Gui Hyun Nam),신동복(Dong Bok Shin),이재훈(Jae Hoon Lee) 대한내과학회 2001 대한내과학회지 Vol.60 No.1
N/A Background : Although cisplatin (CDDP)-based chemotherapy is currently considered to be the most active treatment for advanced non-small cell lung cancer (NSCLC), ultimate prognosis still remains poor. More effective cytotoxic agents are needed to improve outcom of these patients. We evaluated the efficacy and safty of combination chemotherapy with vinorelbine and ifosfamide in patients with advanced NSCLC. Methods : Thirty-three chemotherapy-nave patients with stage IIIB or IV NSCLC were treated with vinorelbine 25 mg/m2 on days 1 & 8 and ifosfamide 2 g/m2 on days 1, 2 & 3 with mesna every 3 weeks. Results : Among thirty evaluable patients who received the vinorelbine/ifosfamide combination chemotherapy, nine (30%) partial responses were observed. With median follow-up duration of 80weeks, the median response duration and overall survival durations were 23 weeks and 38 weeks respectively. World Health Organization grade 3 to 4 neutropenia and anemia occured in 5% and 4.3% respectively. Conclusion : Combination chemotherapy with vinorelbine and ifosfamide is an effective treatment for patients with advanced NSCLC with a manageable toxicity.(Korean J Med 60:70-76, 2001)
감염과 관련된 위점막 조직의 Glutathione에 관한 연구
박동균 ( Dong Kyun Park ),김은수 ( Eun Soo Kim ),홍순홍 ( Soon Hong Hong ),정문기 ( Moon Gi Chun ),권오상 ( Oh Sang Kwon ),김선숙 ( Sun Suk Kim ),구양서 ( Yang Suh Kwon ),김유경 ( Yu Kyun Kim ),최덕주 ( Duck Joo Choi ),박현철 ( Hy 대한소화기학회 2002 대한소화기학회 춘계학술대회 Vol.2002 No.-
<목적> Helicobacter pylori(H. pylori)에 의한 위점막 손상은 H. pylori에 의해 활성화된 염증세포의 산소 유리기 생성 및 자극과 관련이 있다고 알려져 왔고 최근에는 H. pylori 자체에서도 산소 유리기가 발생한다는 연구가 있다. 본 연구에서는 updated Sydney system을 이용한 grading 과 산소 유리기를 간접적으로 측정할 수 있는 glutathione(GSH)의 농도를 분석하여 위점막의 산소유리기와 H
전 대장절제술 후 재발한 회장 크론병 환자에서 발생한 폐동맥 색전증 1예
김주현,박현철,강동훈,김은아,공희상,홍순홍,정찬 대한소화기내시경학회 2001 Clinical Endoscopy Vol.22 No.2
Thromboembolic complications such as deep vein thrombosis, portal and mesenteric vein thrombosis, and pulmonary emboli are rare extraintestinal manifestations of inflammatory bowel disease but are associated with a high morbidity and mortality. The cause of thrombotic complications in inflammatory bowel disease is generally considered to be hypercoagulability. We experienced a case of pulmonary embolism complicated in recurrent ileal Crohn's disease in a 36-year-old female who presented with a sudden onset of dyspnea and hemoptysis. She had taken total colectomy 2 years before due to colonic stricture complicating Crohns disease. An anti-coagulation therapy was successful in managing this rare complication of Crohn's disease.
이기영,이윤정,박혜영,강문호,김홍규,이성광,정연실,홍순홍,정성권,이화은,서찬종 대한내분비학회 2000 Endocrinology and metabolism Vol.15 No.4
Background: Propylthiouracil (PIV) and methimazole (MMI) were widely used for the treatment of hyperthyroidism. Hepatic injury caused by these agents is a rare but serious complication. This study is to investigate the clinical features of hepatotoxicity from antithyroid drugs. Methods: We reviewed 17 cases of hepatic injury during treatment with antithyroid drugs in patients with hyperthyroidism. Included were 6 cases we experienced and 11 cases reported in Korean literature from 1986 to 1999. We analyzed the clinical features of hepatic injury. Results: Of 17 cases of hepatic injury, 12 were PTU cases and 5 MMI cases. The mean age of PTU cases was 40 years with 6/12 patients over 40 years old and 2/5 MMI cases were over 40 years old. The dose of PTU was 300 mg/d or more in 10/12 cases (83%) and the dose of MMI was 30 mg/d in 3/5 cases (60%). The hepatic injury occurred within 3 months in 8/12 PTU cases (67%) and within 2 months in 4/5 MMI cases (80%). The duration of hepatic injury tended to be longer in MMI cases than in PTV cases (median; 80 vs 41 days, p=0.102). In PTU cases, the duration of hepatic injury was correlated with the duration of drug use before hepatic injury (p$lt;0.05). All of 8 biopsied cases who took PTU had predominantly hepatocellular necrosis. Two biopsied cases who took MMI had cholestatic jaundice and nonspecific abnormality, respectively. Biochemical findings of all MMI cases were compatible with cholestatic jaundice. As to the treatment of hyperthyroidism after hepatic injury, 4/12 PTU cases were treated with RAI therapy, 5 with MMI and one with surgery, and treatment was unknown in two. On the other hand 3/5 MMI cases interestingly entered into spontaneous remission after hepatic injury and 2/5 had RAI therapy. Hepatic dysfunction recurred in each one whom treatment by changing to MMI or PTU was tried on. Conclusion: Most of hepatic injury during treatment with antithyroid drugs developed within two to three months of drug use. The hepatic injury related to PTU was mainly cytotoxic whereas that related to MMI was cholestatic. Since there is a cross-reaction between PTU and MMI in hepatotoxicity, RAI therapy or operation shoud be considered as an alternative treatment of hyperthyroidism after hepatic injury (J Kor Soc Endocrinol 15:554-560, 2000).